机构:[1]Department of Pharmacy, Fourth Hospital of Hebei Medical University, Shijiazhuang, China药学部药学部河北医科大学第四医院[2]Department of Breast Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[3]Department of Pharmaceutics, Hebei Medical University, Shijiazhuang, China
National Natural
Science Foundation of China (Nos. 81973251 and 81302725), Hebei
Province Funding Project for Introduced Overseas Personnel (Nos.
C20230351), and Hebei Natural Science Foundation (No. H202206444;
Shijiazhuang, China).
语种:
外文
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2025]版:
大类|2 区医学
小类|2 区医学:研究与实验2 区药学
最新[2025]版:
大类|2 区医学
小类|2 区医学:研究与实验2 区药学
JCR分区:
出版当年[2024]版:
无
最新[2023]版:
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者机构:[1]Department of Pharmacy, Fourth Hospital of Hebei Medical University, Shijiazhuang, China
通讯作者:
推荐引用方式(GB/T 7714):
Zhao Tianyu,Ren Mingli,Shi Jiajie,et al.Engineering the protein corona: Strategies, effects, and future directions in nanoparticle therapeutics[J].BIOMEDICINE & PHARMACOTHERAPY.2024,175:116627.doi:10.1016/j.biopha.2024.116627.
APA:
Zhao Tianyu,Ren Mingli,Shi Jiajie,Wang Haijiao,Bai Jing...&Xiang Bai.(2024).Engineering the protein corona: Strategies, effects, and future directions in nanoparticle therapeutics.BIOMEDICINE & PHARMACOTHERAPY,175,
MLA:
Zhao Tianyu,et al."Engineering the protein corona: Strategies, effects, and future directions in nanoparticle therapeutics".BIOMEDICINE & PHARMACOTHERAPY 175.(2024):116627